AN2 Therapeutics Reports Third-Quarter Loss of $7.96 Million

AN2 Therapeutics reported a third-quarter 2026 net loss of $8.0 million, compared with $9.4 million a year earlier. Research and development expenses were $5.7 million, and the company had $80.2 million in cash, cash equivalents and investments at September 30, 2026. The company also reported regul…